Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

COMP a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker

Hesselstrand, Roger LU ; Kassner, Anja LU ; Heinegård, Dick LU and Saxne, Tore LU (2008) In Annals of the Rheumatic Diseases 67(9). p.1242-1248
Abstract
OBJECTIVE: COMP primarily found in cartilage is thought to be an important regulator of assembly and maintenance of the fibrillar collagen I and II networks. Recently COMP was shown to be produced by skin fibroblasts from patients with systemic sclerosis (SSc, scleroderma). The purpose of this study was to examine whether COMP is released from skin to serum in SSc patients, and may serve as indicator of activity of skin involvement. METHODS: Serum COMP levels were measured by enzyme linked immunosorbent assay in patients with SSc whose skin involvement was assessed with the modified Rodnan skin score (mRss) and high frequency ultrasound. The presence of COMP in skin biopsies was assessed by Western blot using a monoclonal antibody to the... (More)
OBJECTIVE: COMP primarily found in cartilage is thought to be an important regulator of assembly and maintenance of the fibrillar collagen I and II networks. Recently COMP was shown to be produced by skin fibroblasts from patients with systemic sclerosis (SSc, scleroderma). The purpose of this study was to examine whether COMP is released from skin to serum in SSc patients, and may serve as indicator of activity of skin involvement. METHODS: Serum COMP levels were measured by enzyme linked immunosorbent assay in patients with SSc whose skin involvement was assessed with the modified Rodnan skin score (mRss) and high frequency ultrasound. The presence of COMP in skin biopsies was assessed by Western blot using a monoclonal antibody to the very C-terminal end of human COMP. RESULTS: Serum COMP correlated to skin involvement as measured by the mRss (n=70; rS=0.60; p<0.001), to skin thickness measured by ultrasound (n=88; rS=0.55; p<0.001) and inversely to skin echogenicity measured by ultrasound (n=88; rS=-0.40; p<0.001). In 70 patients followed longitudinally there was a correlation between changes in serum COMP (n=307) and changes in mRss (rS=0.35; p=0.008). In individual patients monitored with repeated measurements, serum COMP changes closely paralleled changes in mRss. A C-terminal COMP fragment, with an apparent Mr 56 kDa, was identified in SSc skin biopsies, while no COMP-reactivity was detected in normal skin. CONCLUSION: The high turnover of COMP in SSc skin suggests a pathophysiologic role. Serum COMP shows promise as a new biomarker in SSc. (Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Annals of the Rheumatic Diseases
volume
67
issue
9
pages
1242 - 1248
publisher
BMJ Publishing Group
external identifiers
  • wos:000258395700008
  • pmid:18065498
  • scopus:50249149816
  • pmid:18065498
ISSN
1468-2060
DOI
10.1136/ard.2007.082099
language
English
LU publication?
yes
id
40766575-fadd-4253-bdd6-eb1dc6b20f37 (old id 1035523)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/18065498?dopt=Abstract
date added to LUP
2016-04-01 13:42:32
date last changed
2022-04-06 06:33:25
@article{40766575-fadd-4253-bdd6-eb1dc6b20f37,
  abstract     = {{OBJECTIVE: COMP primarily found in cartilage is thought to be an important regulator of assembly and maintenance of the fibrillar collagen I and II networks. Recently COMP was shown to be produced by skin fibroblasts from patients with systemic sclerosis (SSc, scleroderma). The purpose of this study was to examine whether COMP is released from skin to serum in SSc patients, and may serve as indicator of activity of skin involvement. METHODS: Serum COMP levels were measured by enzyme linked immunosorbent assay in patients with SSc whose skin involvement was assessed with the modified Rodnan skin score (mRss) and high frequency ultrasound. The presence of COMP in skin biopsies was assessed by Western blot using a monoclonal antibody to the very C-terminal end of human COMP. RESULTS: Serum COMP correlated to skin involvement as measured by the mRss (n=70; rS=0.60; p&lt;0.001), to skin thickness measured by ultrasound (n=88; rS=0.55; p&lt;0.001) and inversely to skin echogenicity measured by ultrasound (n=88; rS=-0.40; p&lt;0.001). In 70 patients followed longitudinally there was a correlation between changes in serum COMP (n=307) and changes in mRss (rS=0.35; p=0.008). In individual patients monitored with repeated measurements, serum COMP changes closely paralleled changes in mRss. A C-terminal COMP fragment, with an apparent Mr 56 kDa, was identified in SSc skin biopsies, while no COMP-reactivity was detected in normal skin. CONCLUSION: The high turnover of COMP in SSc skin suggests a pathophysiologic role. Serum COMP shows promise as a new biomarker in SSc.}},
  author       = {{Hesselstrand, Roger and Kassner, Anja and Heinegård, Dick and Saxne, Tore}},
  issn         = {{1468-2060}},
  language     = {{eng}},
  number       = {{9}},
  pages        = {{1242--1248}},
  publisher    = {{BMJ Publishing Group}},
  series       = {{Annals of the Rheumatic Diseases}},
  title        = {{COMP a candidate molecule in the pathogenesis of systemic sclerosis with a potential as a disease marker}},
  url          = {{http://dx.doi.org/10.1136/ard.2007.082099}},
  doi          = {{10.1136/ard.2007.082099}},
  volume       = {{67}},
  year         = {{2008}},
}